To investigate the metabolic circuits affected by MET RTK activity and its targeted inhibition, a panel of 10 cellular models of MET-positive cell lines including seven MET-driven (GTL-16, MKN45, KATOII, SNU638, Hs746T, EBC-1, H1993) and three non-MET-driven cancer cell lines (H1648, H820, and HCC827) has been used. This evidence concerns the gene MET and cancer.